• Julie Kanter, MD is the director of the UAB Adult Sickle Cell Clinic and associate professor in the Division of Hematology and Oncology. Her clinical and research interests in sickle cell disease include improving access to care for affected individuals, and identifying and developing novel therapies for sickle cell disease, as well as enhancing horizontal care for patients with sickle cell disease. Kanter comes to UAB from the Medical University of South Carolina, where she was director of sickle cell disease research. Kanter also co-directs the UAB Comprehensive Sickle Cell Disease Center.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Annals On Call - Vascular Occlusive Crisis: Site of Care MattersAnnals of Internal Medicine.  174:OC1-OC1. 2021
    2021 American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantationBlood Advances.  5:3668-3689. 2021
    2021 One Small Step for Sickle Cell Disease: Many More to Go.Annals of Internal Medicine.  174:1313-1314. 2021
    2021 Kneeling Was the First Step for Sickle Cell DiseaseAnnals of Internal Medicine.  174:1004-1005. 2021
    2021 Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults with Sickle Cell Disease: A Randomized Clinical Trial 2021
    2021 Definity, an affinity for painful crisis: a case series describing vaso-occlusive pain crises in sickle cell patients undergoing echocardiogram with Definity contrast 2021
    2021 Transcranial doppler screening in a current cohort of children with sickle cell anemia: Results from the DISPLACE StudyJournal of Pediatric Hematology/Oncology2021
    2020 Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium. 2020
    2020 Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell diseaseBlood.  136:623-626. 2020
    2020 Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell diseaseBlood Advances.  4:2058-2063. 2020
    2020 Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium 2020
    2020 An unusual ultrasound appearance of renal hemosiderosis in acute sickle cell nephropathyRadiology Case Reports.  15:26-30. 2020
    2020 Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.Therapeutic Advances in Hematology.  11:2040620720955000. 2020
    2019 International Differences in Outpatient Pain Management: A Survey of Sickle Cell Disease.Journal of Clinical Medicine.  8. 2019
    2019 Health-related Quality of Life in Children With Sickle Cell Disease Undergoing Chronic Red Cell Transfusion TherapyJournal of Pediatric Hematology/Oncology.  41:307-312. 2019
    2019 Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemiaBritish Journal of Haematology.  184:1058-1061. 2019
    2019 Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb studyBritish Journal of Haematology.  184:269-278. 2019
    2018 Crizanlizumab. Anti-P-selectin monoclonal antibody, Prevention of sickle-cell-related pain crisesDrugs of the future.  43:489-489. 2018
    2013 Management of sickle cell disease from childhood through adulthoodBlood Reviews.  27:279-287. 2013

    Principal Investigator On

  • 1/2 Sickle Cell Disease and CardioVascular Risk-Red Cell Exchange Trial (SCDCARRE Trial)  awarded by University of Pittsburgh The
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • ALSTATE (Alabama Lifespan Sickle Cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • ALSTATE (Alabama Lifespan Sickle Cell Tracking Access Towards Equality) Network  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • DISPLACE: Dissemination and Implementation of Stroke Prevention Looking at the Care Environment  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Hydroxyurea Pharmacokinetics and Pharmacodynamics in Adults with Sickle Cell Anemia  awarded by CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI)
  • Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC)  awarded by Medical University of South Carolina
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by IMARA INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by CYCLERION THERAPEUTICS INC
  • Private Grant  awarded by BAXALTA US INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by IMARA INC.
  • Private Grant  awarded by BLUEBIRD BIO INC.
  • Private Grant  awarded by FORMA THERAPEUTICS
  • Sickle Cell Disease and Cardiovascular Risk-Red Cell Exchange Trial (SCD-CARRE)  awarded by University of Pittsburgh The
  • Sickle Cell Treatment Demonstration Program  awarded by Health Resources and Services Administration/DHHS
  • Sickle Cell Treatment Demonstration Program - EMBRACE  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Education And Training

  • Doctor of Medicine, Tulane University 2004
  • Bachelor of Arts in Biology, Washington University/St. Louis 1999
  • Full Name

  • Julie Kanter